Personalized Medicine’s Effect on Oncologists’ Treatment Regimens

  • ID: 4035476
  • Report
  • Region: Global
  • 59 Pages
  • Industry Standard Research (ISR)
1 of 4

One aspect of personalized medicine is certain; it is complicated. If you happen to have a highly scientific background, you actually may be able to define the term. However, if you polled five people very familiar with personalized medicine, you should expect to hear five different definitions. The researcher wanted to understand where oncologists stand on the topic of personalized medicine.

101 US based, board-certified oncologists were inteviewed to gather their views on how familiar they are with personalized medicine, how they are treating patients, what tests are being used and which will be used more, and how their patient treatment regimens could evolve in the future.

What You Will Learn:

  • Oncologists’ familiarity with personalized medicine, and perceptions related to hype vs. tangible benefit
  • Future predictions for the use and benefits related to personalized medicine in oncology, including potential hurdles to adoption
  • Percentage of patients requesting personalized medicine vs. percentage of oncologists suggesting personalized medicine to patients
  • Current number of patients treated using genetic tumor profiling vs. oncologists’ predictions for the number in 3 years
  • Oncologists’ interest in conducting clinical trials using genetic tumor profiling
  • What tests oncologists perform, and how the data are used and stored for use in future clinical trials

Major Sections:

  • Current Landscape
  • Genetic Tests and Patient Care
  • Clinical Trial Views
Note: Product cover images may vary from those shown
2 of 4

1. Copyright And Usage Guide

2. Introduction

3. Methodology

4. Statistical Significance

5. Respondent Qualifications

  • Practice Area
  • Years In Practice
  • Types Of Cancer Treated
  • Primary Practice Setting

6. Current Landscape

  • Section Takeaways
  • Oncologist Familiarity With Personalized Medicine
  • Statistical Differences
  • Current Perceptions Of Hype Vs. Benefit
  • Future Perceptions Of Hype Vs. Benefit
  • Statistical Differences
  • Willingness Of Payers To Pay For Panel Tests

7. Genetic Tests And Patient Care

  • Section Takeaways
  • Prevalence Of Patients Asking For Personalized Treatments
  • Statistical Differences
  • Asking Patients About Completing A Genetic Profile
  • Statistical Differences
  • Percent Of Patients With A Completed Genetic Profile
  • Statistical Differences
  • Percent Of Patients Treated Using Genetic Tumor Profiling
  • Current Percentage
  • Future Percentage
  • Statistical Differences – Current Treatments
  • Statistical Differences – Future Treatments
  • Hurdles Preventing Widespread Use Of Personalized Medicine
  • Statistical Differences
  • Tests Used To Evaluate Patients’ Immune Response To Tumors
  • Current Percentage
  • Future Percentage
  • Statistical Differences – Current Use
  • Statistical Differences – Future Use
  • Value Of Running Tests In Development Vs. Commercialization
  • Predictions For The Biggest Treatment Advancements In Five Years

8. Clinical Trial Views

  • Section takeaways
  • Genetic tumor profiling and clinical trial interest
  • Using genetic data to match patients for Clinical Trials
  • Statistical differences
  • Trial protocol: Broad vs. Sub-set indication

9. Demographics

  • Patient volume
  • Direct patient care
  • Influence on others practicing oncology
  • KOL-type activities

10. Just As We Were Going To Press

  • Under US Precision Medicine Initiative, NIH to Collect Data from at Least 1M people by 2019 Direct Patient Care
Note: Product cover images may vary from those shown
3 of 4


4 of 4
Note: Product cover images may vary from those shown